
    
      Participants receiving pembrolizumab who attain a complete response (CR) may consider
      stopping trial treatment if they meet criteria for holding therapy. Participants who stop
      trial treatment after receiving 24 months of trial treatment for reasons other than
      progressive disease (PD) or intolerability, or participants who attain a CR and stop trial
      treatment may be eligible for up to one year of retreatment upon experiencing PD.
    
  